Research demonstrates improved targeted delivery of nanocarriers in acute kidney injury, suggesting new treatment avenues.
While nanomedicine holds great promise for kidney disease, targeted delivery remains a major challenge. Most nanocarriers rely on passive accumulation or epithelial-specific ligands, limiting their utility in complex, inflamed renal...
No takes yet. Share an insight, caveat, or question.
Bishop et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: